{"id":"W3147842235","doi":"10.1016/s1556-0864(21)02027-x","title":"185TiP A phase Ib dose-escalation study evaluating trastuzumab deruxtecan (T-DXd) and durvalumab in combination with chemotherapy as first-line treatment in patients with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (DESTINY-Lung03)","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Internal medicine; Oncology; Pemetrexed; Carboplatin; Nivolumab; Trastuzumab; Phases of clinical research; Lapatinib; Immunotherapy; Chemotherapy; Cancer; Cisplatin; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008954561,0.001153235,0.001665674,0.0004462992,0.0002903847,0.0011548,0.0008415315,0.0009583913,0.004797277],"category_scores_gemma":[0.0005429529,0.0005792928,0.001342435,0.0004590398,0.0007734158,0.0005882947,0.0003297017,0.003048845,0.001079568],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001227903,"about_ca_system_score_gemma":0.001262453,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001774561,"about_ca_topic_score_gemma":0.004545765,"domain_scores_codex":[0.9996493,0.0001296552,0.00001754411,0.00006358417,0.00003254383,0.0001073915],"domain_scores_gemma":[0.9995783,0.00005470199,0.00006850902,0.0000405296,0.00002110271,0.000236812],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7495857,0.07162944,0.008099485,0.0006007414,0.002278078,0.0002504845,0.0002634791,0.003755587,0.05800873,0.0005466574,0.005149771,0.0998319],"study_design_scores_gemma":[0.6377071,0.3387941,0.01404469,0.00002641701,0.0006705776,0.0001863864,0.00005030102,0.001370386,0.003728431,0.0001957396,0.003198056,0.00002773965],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924453,0.001043592,0.0004064299,0.0003678428,0.0001479479,0.001461076,0.001753781,0.0001022411,0.002271811],"genre_scores_gemma":[0.9871502,0.001228313,0.001478995,0.0009374522,0.00015011,0.001383244,0.003818347,0.00003603907,0.00381718],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004797277,"threshold_uncertainty_score":0.01604849,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02310524928284638,"score_gpt":0.4414060840061778,"score_spread":0.4183008347233313,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}